Company intelligence / Profile preview

Phalanx Labs

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Phalanx is a biotechnology company developing a next-generation platform for programmable medicines, specifically focusing on advanced non-viral RNA delivery. Co-founded by RNA delivery pioneer James Dahlman and Sahil Chopra, the company utilizes a high-throughput, DNA-barcoded screening platform to identify delivery vehicles capable of reaching extrahepatic tissues. This approach aims to overcome the primary bottleneck in genetic medicine: the precise delivery of mRNA and other nucleic acids to specific organs and cell types. Phalanx is currently in the pre-clinical stage, leveraging its platform to build a pipeline of targeted genetic therapies.

Therapeutic areas: OncologyRare Diseases
Modalities: RNA therapymRNA-based drugsLipid nanoparticle delivery therapyNon-viral delivery
Industry: Biotech

Beyond the preview

Go deeper on Phalanx Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phalanx Labs.

Explore the full profile